Measuring the Treatment Preferences of Participants in Japan With Moderate-to-Severe Psoriasis (PsO) Using Discrete Choice Experiment (DCE)

Bristol-Myers Squibb (BMS)

Status: Completed

Conditions: Psoriasis

Study type: Observational

Funder types: Industry

Identifiers

NCT05065762

IM011-174

Details and patient eligibility

About

The purpose of this observational study is to identify and weight the treatment attributes from the moderate-to-severe Psoriasis (PsO) patients' perspective in Japan.

Enrollment: 232 patients

Sex: All

Ages: 20+ years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Diagnosis of moderate-to-severe Psoriasis (PsO) by physician (phase 1) or self-reported (phase 2)
• Currently taking systemic psoriasis treatment
• Japanese resident aged 20 years and older

Exclusion criteria

• Unable or unwilling to provide informed consent
• Diagnosis of guttate, inverse, pustular, erythrodermic, or drug-induced psoriasis

Trial design

232 participants in 2 patient groups

Phase 1

Description:

Participants with moderate-to-severe Psoriasis (PsO) in Japan who have been recruited based on eligibility criteria

Phase 2

Description:

Self-reported moderate-to-severe Psoriasis (PsO) participants in Japan